Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.
Staburo GmbH, Munich, Germany.
Lung. 2024 Oct;202(5):595-599. doi: 10.1007/s00408-024-00742-x. Epub 2024 Sep 6.
We investigated whether a 52-gene signature was associated with transplant-free survival and other clinically meaningful outcomes in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry, which enrolled patients who were and were not taking antifibrotic therapy.
The 52-gene risk signature was implemented to classify patients as being at "high risk" or "low risk" of disease progression and mortality. Transplant-free survival and other outcomes were compared between patients with a low-risk versus high-risk signature.
The 52-gene signature classified 159 patients as at low risk and 86 as at high risk; in these groups, respectively, 56.6% and 51.2% used antifibrotic therapy at enrollment. Among those taking antifibrotic therapy, patients with a low-risk versus high-risk signature were at decreased risk of death, a composite of lung transplant or death, and a composite of decline in DLco % predicted > 15%, lung transplant, or death. Similar results were observed in the overall cohort.
These data suggest that the 52-gene signature can be used in patients with IPF treated with antifibrotic therapy to distinguish patients at higher risk of disease progression and mortality.
我们研究了在特发性肺纤维化（IPF）患者的 IPF-PRO 登记处中，52 个基因特征是否与无移植生存和其他有临床意义的结局相关，该登记处纳入了正在接受和未接受抗纤维化治疗的患者。
该 52 个基因风险特征用于将患者分类为疾病进展和死亡率的“高风险”或“低风险”。比较低风险和高风险特征患者之间的无移植生存和其他结局。
该 52 个基因特征将 159 名患者分类为低风险，86 名患者分类为高风险；在这些组中，分别有 56.6%和 51.2%的患者在入组时使用了抗纤维化治疗。在接受抗纤维化治疗的患者中，低风险与高风险特征患者的死亡、肺移植或死亡的复合结局，以及下降>15%、肺移植或死亡的复合结局的风险降低。在整个队列中也观察到了类似的结果。
这些数据表明，52 个基因特征可用于接受抗纤维化治疗的 IPF 患者，以区分疾病进展和死亡率较高的患者。
